In this published text, we found two typographical errors and one capitalization error. The first error was not capitalized ELISA in page 1533, Figure 2 legend line 3. The correction is “using ELISA assay” not “using Elisa assay”. The second one was two typographical errors which were not correct spelling in page 1533, Figure 2 legend Line 7 & 8 and page 1537, Figure 5 legend line 6 & 7. The correct ones are “Results were quantified” and “Quantification of TGF-β1” instead of “Results were qualified” (both instances) and “Qualification of TGF-β1” (both instances). In addition, this article contained inadvertent misapplications of two images: 1. The Baicalein+Co panel for MDA-MB-231 in Figure 4B; 2. The F4/80 marker image for 231/M2 in Figure 5D. We hereby issue this erratum to replace the incorrect figures and document these corrections. Importantly, these updates do not affect the original conclusions of the study. The authors sincerely apologize for any confusion or concern these errors may have caused. The corrected Figures 4 and 5 are as follows.
Figure 4.
Baicalein inhibits enhanced EMT of breast cancer cells induced by M2 macrophages. A. Ki67 expression of MDA-MB-231 and MCF-7 after co-culture with M2 macrophages, M2 macrophages treated with baicalein, M2 macrophages treated with baicalein plus TGF-β1 separately. B. Invasion of MDA-MB-231 and MCF-7 after co-culture with M2 macrophages, M2 macrophages treated with baicalein and M2 macrophages treated with baicalein plus TGF-β1 separately. C. Protein expression of TGF-β1, E-cadherin, N-cadherin, Vimentin, t-AKT and p-AKT of MDA-MB-231 and MCF-7 before and after co-culture with M2 macrophages or M2 macrophages treated with baicalein. Values were represented as mean ± SD. *P<0.05, **P<0.01. Scale bar = 50 μm. Co, co-culture.
Figure 5.
Baicalein suppresses breast cancer in vivo. A. Primary tumors were collected from MDA-MB-231, MDA-MB-231/M2 and MDA-MB-231/M2/baicalein groups. B. Growth curve of primary tumors in BALB/c nude mice. Tumor volume was described as mean ± SD (mm3). C. Quantification of lung lesions for each group, data was represented as percentage of lesion area of lung tissue. D. TGF-β1, F4/80, CD206, iNOS, E-cadherin, N-cadherin, Vimentin and p-AKT expression of primary tumors by immunohistochemistry. E. TGF-β1, CD206, iNOS and p-AKT expression of lung lesions by immunohistochemistry. F. Quantification of TGF-β1, CD206, iNOS and p-AKT expression of lung lesions. G. Quantification of TGF-β1, F4/80, CD206, iNOS, E-cadherin, N-cadherin, Vimentin and p-AKT expression of primary tumor. Scale bar = 50 μm. *P<0.05, **P<0.01, ***P<0.001.